PROSTATE CANCER DETECTION USING MASS-SPECTROMETRIC PROFILING OF LOW-MOLECULAR WEIGHT BLOOD PROTEOME


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, there are no reliable biomarkers of blood plasma for early detection of prostate cancer (PC), a one of the most common malignancies in men. This study developed, universalized and tested a new standardized methodology of detection of prostate cancer biomarkers - profiling of low-molecular weight proteome of blood plasma (1-17 kDa). This approach includes three main components: a preliminary sample preparation, time-of-flight mass spectrometry with an matrix-assisted laser desorption/ionization ALDI-TOF-MS), and the processing of data using bioinformatics software package. The potentials and prospects of the approach developed for identification of potential PC markers are demonstrated. 46 samples of blood plasma of PC patients and 26 controls were screened. This evaluation identified peptides/polypeptides that have the potential to be used for the detection of disease.

Full Text

Restricted Access

References

  1. Damber J.E., Aus G. Prostate cancer. Lancet 2008;371 (9625): 1710—1721.
  2. Freedland S.J., Partin A.W. Prostate-specific antigen: update 2006. Urology 2006;67(3):458—460.
  3. Thompson I.M., Ankerst D.P., Chi C. et.al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294(1):66—70.
  4. Schroder F.H., van der Cruijsen-Koeter I., de Koning H.J. et.al. Prostate cancer detection at low prostate specific antigen. J Urol 2000;163(3):806—812.
  5. Tirumalai R.S., Chan K.C., Prieto D.A. et al. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003;2(10):1096—1103.
  6. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1(11):845—867.
  7. Al-Ruwaili J.A., Larkin S.E., Zeidan B.A. et al. Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis. Cancer Genomics Proteomics 2010;7(2):93—103.
  8. Qu Y., Adam B.L., Yasui Y. et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48(10):1835—1843.
  9. Petricoin E.F., 3rd, Ornstein D.K., Paweletz C.P. et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94(20):1576—1578.
  10. Banez L.L., Prasanna P., Sun L. et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003;170(2 Pt 1): 442—446.
  11. Adam B.L., Qu Y., Davis J.W et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62(13):3609—3614.
  12. Lawrie L.C., Curran S., McLeod H.L. et al. Application of laser capture microdissection and proteomics in colon cancer. Mol Pathol 2001;54(4):253—258.
  13. Vlahou A., Schellhammer P.F., Mendrinos S. et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001; 158(4):1491—1502.
  14. Ketterlinus R., Hsieh S.Y., Teng S.H. et al. Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. Biotechniques 2005;Suppl:37—40.
  15. Petricoin E.F., Ardekani A.M., Hitt B.A. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359(9306):572—577.
  16. Rai A.J., Zhang Z., Rosenzweig J. et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002; 126(12):1518—1526.
  17. Villanueva J., Philip J., Entenberg D. et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 2004; 76(6):1560—1570.
  18. Шевченко В.Е., Арноцкая Н.Е., Трифонова О.П. и др. Профилирование низкомолекулярного протеома плазмы крови для обнаружения потенциальних маркеров рака легкого. Масс-спектрометрия 2007; 4(4): 245—254.
  19. Shevchenko V.E., Arnotskaya N.E., Zaridze D.G. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry. Eur J Mass Spectrom 2010;16(4):539—49.
  20. Pyatnitskiy M.A., Lisitsa A.V., Moshkovskii S.A. et al. Identification of differential signs of squamous cell lung carcinoma by means of the mass spectrometry profiling of blood plasma. Journal of Analytical Chemistry 2011; 66 (14):1369—1375.
  21. Шевченко В.Е., Мадина Х., Поддубная И.В. и др. Масс-спектрометрическое профилирование низкомолекулярного протеома плазми крови для обнаружения потенциальних маркеров рака молочной желези. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2011;22 (3):27—33.
  22. Ornstein D.K., Rayford W., Fusaro V.A. et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 2004;172(4 Pt 1):1302—1305.
  23. Kohli M., Siegel E., Bhattacharya S. et al. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark 2006;2(6):249—258.
  24. Baggerly K.A., Morris J.S., Coombes K.R. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004;20(5):777—785.
  25. Petricoin E.F., Ornstein D.K., Liotta L.A. Clinical proteomics: Applications for prostate cancer biomarker discovery and detection. Urol Oncol 2004;22(4):322—328.
  26. M'Koma A.E., Blum D.L., Norris J.L. et al. Detection of preneoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem Biophys Res Commun 2007;353(3):829—834.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies